A citation-based method for searching scientific literature

N Ari Wijetunga, Yao Yu, Luc G Morris, Nancy Lee, Nadeem Riaz. Oral Oncol 2021
Times Cited: 4







List of co-cited articles
8 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer.
Anthony R Cillo, Cornelius H L Kürten, Tracy Tabib, Zengbiao Qi, Sayali Onkar, Ting Wang, Angen Liu, Umamaheswar Duvvuri, Seungwon Kim, Ryan J Soose,[...]. Immunity 2020
98
50

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Barbara Burtness, Kevin J Harrington, Richard Greil, Denis Soulières, Makoto Tahara, Gilberto de Castro, Amanda Psyrri, Neus Basté, Prakash Neupane, Åse Bratland,[...]. Lancet 2019
596
50

Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors.
Oliver Wood, Jeongmin Woo, Gregory Seumois, Natalia Savelyeva, Katy J McCann, Divya Singh, Terry Jones, Lailah Peel, Michael S Breen, Matthew Ward,[...]. Oncotarget 2016
56
50

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Ezra E W Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra, Myung-Ju Ahn, Ainara Soria, Jean-Pascal Machiels, Nicolas Mach, Ranee Mehra,[...]. Lancet 2019
529
50

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.
Joshua Bauml, Tanguy Y Seiwert, David G Pfister, Francis Worden, Stephen V Liu, Jill Gilbert, Nabil F Saba, Jared Weiss, Lori Wirth, Ammar Sukari,[...]. J Clin Oncol 2017
329
50

The head and neck cancer immune landscape and its immunotherapeutic implications.
Rajarsi Mandal, Yasin Şenbabaoğlu, Alexis Desrichard, Jonathan J Havel, Martin G Dalin, Nadeem Riaz, Ken-Wing Lee, Ian Ganly, A Ari Hakimi, Timothy A Chan,[...]. JCI Insight 2016
298
50

Head and neck squamous cell carcinoma.
Daniel E Johnson, Barbara Burtness, C René Leemans, Vivian Wai Yan Lui, Julie E Bauman, Jennifer R Grandis. Nat Rev Dis Primers 2020
166
50

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
R L Ferris, R Haddad, C Even, M Tahara, M Dvorkin, T E Ciuleanu, P M Clement, R Mesia, S Kutukova, L Zholudeva,[...]. Ann Oncol 2020
68
50

Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
Andrew Woolston, Khurum Khan, Georgia Spain, Louise J Barber, Beatrice Griffiths, Reyes Gonzalez-Exposito, Lisa Hornsteiner, Marco Punta, Yatish Patil, Alice Newey,[...]. Cancer Cell 2019
77
25

Epigenetic therapy in immune-oncology.
Peter A Jones, Hitoshi Ohtani, Ankur Chakravarthy, Daniel D De Carvalho. Nat Rev Cancer 2019
163
25





Comprehensive immunogenomic landscape analysis of prognosis-related genes in head and neck cancer.
Lei Li, Xiao-Li Wang, Qian Lei, Chuan-Zheng Sun, Yan Xi, Ran Chen, Yong-Wen He. Sci Rep 2020
12
25

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy.
Diego Chowell, Luc G T Morris, Claud M Grigg, Jeffrey K Weber, Robert M Samstein, Vladimir Makarov, Fengshen Kuo, Sviatoslav M Kendall, David Requena, Nadeem Riaz,[...]. Science 2018
419
25

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.
Zachary R Chalmers, Caitlin F Connelly, David Fabrizio, Laurie Gay, Siraj M Ali, Riley Ennis, Alexa Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki,[...]. Genome Med 2017
25

Integrative Analysis of Multi-omics Data Identified EGFR and PTGS2 as Key Nodes in a Gene Regulatory Network Related to Immune Phenotypes in Head and Neck Cancer.
Bohai Feng, Ying Shen, Xavier Pastor Hostench, Matthias Bieg, Michaela Plath, Naveed Ishaque, Roland Eils, Kolja Freier, Wilko Weichert, Karim Zaoui,[...]. Clin Cancer Res 2020
18
25

An Immune-Related Gene Prognostic Index for Head and Neck Squamous Cell Carcinoma.
Yue Chen, Zhi-Yong Li, Guan-Qun Zhou, Ying Sun. Clin Cancer Res 2021
18
25

The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape.
Daniel N Weinberg, Simon Papillon-Cavanagh, Haifen Chen, Yuan Yue, Xiao Chen, Kartik N Rajagopalan, Cynthia Horth, John T McGuire, Xinjing Xu, Hamid Nikbakht,[...]. Nature 2019
123
25

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load.
Hyunchul Jung, Hong Sook Kim, Jeong Yeon Kim, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park, Manel Esteller, Se-Hoon Lee, Jung Kyoon Choi. Nat Commun 2019
77
25


The current landscape of single-cell transcriptomics for cancer immunotherapy.
Puneeth Guruprasad, Yong Gu Lee, Ki Hyun Kim, Marco Ruella. J Exp Med 2021
6
25

Development of immune checkpoint therapy for cancer.
Jill M Fritz, Michael J Lenardo. J Exp Med 2019
69
25

Changes in the expression of Col IV, gelatinase and TIMP-1 in oral leukoplakia.
Zhihui Zhang, Weiwei Guo, Yan Zhang, Xiao Wang, Hongwei Liu, Si Xu, Zhongfang Zhao, Danyang Chen. Int J Clin Exp Pathol 2017
1
100

Immune profiles in primary squamous cell carcinoma of the head and neck.
Vassiliki Saloura, Evgeny Izumchenko, Zhixiang Zuo, Riyue Bao, Michael Korzinkin, Ivan Ozerov, Alex Zhavoronkov, David Sidransky, Atul Bedi, Mohammad O Hoque,[...]. Oral Oncol 2019
28
25

PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Jin Wang, Tongxin Xie, Bingbing Wang, William N William, John V Heymach, Adel K El-Naggar, Jeffrey N Myers, Carlos Caulin. Cancer Prev Res (Phila) 2017
26
25

Blockade of PD-1 effectively inhibits in vivo malignant transformation of oral mucosa.
Yichen Chen, Qiusheng Li, Xinye Li, Da Ma, Juan Fang, Liqun Luo, Xiangqi Liu, Xi Wang, Vivian Wai Yan Lui, Juan Xia,[...]. Oncoimmunology 2017
10
25

The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy.
Daniela Bruni, Helen K Angell, Jérôme Galon. Nat Rev Cancer 2020
167
25

Treatment after progression in the era of immunotherapy.
Salem Billan, Orit Kaidar-Person, Ziv Gil. Lancet Oncol 2020
29
25

PD-Loma: a cancer entity with a shared sensitivity to the PD-1/PD-L1 pathway blockade.
Laure Hirsch, Laurence Zitvogel, Alexander Eggermont, Aurelien Marabelle. Br J Cancer 2019
40
25

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
25

Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma.
Jose A Monteiro de Oliveira Novaes, Taghreed Hirz, Irene Guijarro, Monique Nilsson, Marlese A Pisegna, Alissa Poteete, Hampartsoum B Barsoumian, Jared J Fradette, Limo N Chen, Don L Gibbons,[...]. Cancer Prev Res (Phila) 2021
5
25

Understanding adverse events of immunotherapy: A mechanistic perspective.
Kelly P Burke, Stephanie Grebinoski, Arlene H Sharpe, Dario A A Vignali. J Exp Med 2021
7
25

SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.
Michael S Leibowitz, Raghvendra M Srivastava, Pedro A Andrade Filho, Ann Marie Egloff, Lin Wang, Raja R Seethala, Soldano Ferrone, Robert L Ferris. Clin Cancer Res 2013
53
25

Methylation of immune synapse genes modulates tumor immunogenicity.
Anders Berglund, Matthew Mills, Ryan M Putney, Imène Hamaidi, James Mulé, Sungjune Kim. J Clin Invest 2020
12
25

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker.
Denis L Jardim, Aaron Goodman, Debora de Melo Gagliato, Razelle Kurzrock. Cancer Cell 2021
35
25

Global trends in oral and pharyngeal cancer incidence and mortality.
Cristina Bosetti, Greta Carioli, Claudia Santucci, Paola Bertuccio, Silvano Gallus, Werner Garavello, Eva Negri, Carlo La Vecchia. Int J Cancer 2020
20
25

B cells and cancer: To B or not to B?
Wolf Herman Fridman, Florent Petitprez, Maxime Meylan, Tom Wei-Wu Chen, Cheng-Ming Sun, Lubka T Roumenina, Catherine Sautès-Fridman. J Exp Med 2021
9
25

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Dan P Zandberg, Alain P Algazi, Antonio Jimeno, James S Good, Jérôme Fayette, Nathaniel Bouganim, Neal E Ready, Paul M Clement, Caroline Even, Raymond W Jang,[...]. Eur J Cancer 2019
89
25

Monitoring immune-checkpoint blockade: response evaluation and biomarker development.
Mizuki Nishino, Nikhil H Ramaiya, Hiroto Hatabu, F Stephen Hodi. Nat Rev Clin Oncol 2017
393
25

Human papillomavirus-related oropharyngeal cancer.
M Taberna, M Mena, M A Pavón, L Alemany, M L Gillison, R Mesía. Ann Oncol 2017
145
25

APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Daniel L Faden, Fei Ding, Yan Lin, Shuyan Zhai, Fengshen Kuo, Timothy A Chan, Luc G Morris, Robert L Ferris. Oral Oncol 2019
22
25

Epidemiology and Molecular Biology of Head and Neck Cancer.
Adriana Jou, Jochen Hess. Oncol Res Treat 2017
71
25

Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival.
Mary A Wood, Benjamin R Weeder, Julianne K David, Abhinav Nellore, Reid F Thompson. Genome Med 2020
28
25

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
25

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control.
Jan P Böttcher, Eduardo Bonavita, Probir Chakravarty, Hanna Blees, Mar Cabeza-Cabrerizo, Stefano Sammicheli, Neil C Rogers, Erik Sahai, Santiago Zelenay, Caetano Reis e Sousa. Cell 2018
553
25

Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2).
Nune Markosyan, Jinyang Li, Yu H Sun, Lee P Richman, Jeffrey H Lin, Fangxue Yan, Liz Quinones, Yogev Sela, Taiji Yamazoe, Naomi Gordon,[...]. J Clin Invest 2019
56
25

Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
Aleix Prat, Alejandro Navarro, Laia Paré, Noemí Reguart, Patricia Galván, Tomás Pascual, Alex Martínez, Paolo Nuciforo, Laura Comerma, Llucia Alos,[...]. Cancer Res 2017
180
25

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Filipe Martins, Latifyan Sofiya, Gerasimos P Sykiotis, Faiza Lamine, Michel Maillard, Montserrat Fraga, Keyvan Shabafrouz, Camillo Ribi, Anne Cairoli, Yan Guex-Crosier,[...]. Nat Rev Clin Oncol 2019
413
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.